Currently Viewing:
North American Neuroendocrine Tumor Society Symposium 2018
Dr Thorvardur Halfdanarson Discusses Lack of Risk Factors, Biomarkers in NETs
December 04, 2018
Dr Thorvardur Halfdanarson: Access Is a Big Management Challenge in NETs
November 20, 2018
Dr Thorvardur Halfdanarson on Diagnostics in NETs
November 08, 2018
Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs
November 06, 2018
Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future
November 01, 2018
Dr Thorvardur Halfdanarson on if He Thinks There's a Future For Immunotherapy in NETs
October 23, 2018
Dr Scott Paulson on Standard of Treatment, Novel Approaches Being Taken in GEP-NETs
October 19, 2018
Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs
October 17, 2018
Research at NANETS Cites Value of Genetic Testing in Neuroendocrine Tumors
October 07, 2018
A Comprehensive Look at Updates, Developments in NETs
October 07, 2018
An Update on Lung NET Guidelines
October 07, 2018
Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs
October 07, 2018
Sequencing of Lanreotide Can Improve Outcomes in Patients With Advanced GEP-NETs
October 06, 2018
Currently Reading
Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape
October 06, 2018
Debating Best First-Line Treatment in Well-Differentiated G3 NENs
October 06, 2018
Examining the Benefits of Integrative Oncology, Nutrition in NETs
October 05, 2018
Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs
October 05, 2018
Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs
October 05, 2018
Measuring Quality of Life Among Patients With Neuroendocrine Tumors
October 05, 2018

Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape

The biggest challenge we have right now is how to sequence all of these therapies and how to pick the right patient to sequence those treatments, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.


The biggest challenge we have right now is how to sequence all of these therapies and how to pick the right patient to sequence those treatments, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.

Transcript

What are some of the biggest challenges in the treatment landscape of neuroendocrine tumors currently?

I think that the biggest challenge that we have now is really how to sequence all of these therapies. To start, if you can cut them out, cut them out. But, when you’re at a point that you’re having to use medical therapies, the biggest confusion we have now is we’ve got a whole mix of different things to use and we’re really not sure of the right sequencing for it and how to pick the right patient to sequence those treatments.

In other words, say pancreatic neuroendocrine tumors [NETs]. Should we be using capecitabine and temozolomide before we should be using peptide receptor radionuclide therapy [PRRT], or vice versa? Those decisions, we really don’t have a lot of information. We’ve had a lot of new drugs come in and not a lot of information on how to take a patient through that entire treatment algorithm.

I usually tell patients they’re going to see every treatment we can get to them, but what’s the most optimal strategy for taking them 1, 2, 3, 4, 5 through that regimen is not really known. So, I think that’s a big challenge.

I think the intermediate high-grade or the well-differentiated G3, which is kind of the new pathologic assessment of these tumors is a challenging group. We don’t know if chemotherapy serves those patients best or if they’re better served with things like PRRT, and there was certainly a spirited debate about that this morning. I don’t think that question is really answered, and that treatment needs to be individualized and it often leaves a lot of hand ringing for the oncologist.

I think the final biggest challenge is lung. I think lung has had a lot of disservice in a lot of different clinical trials. So, we’re starting to see a lot more focus on lung NETs as a specific entity and hopefully get a little more data so we know what we’re doing in that setting.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!